Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Study period:
1982-10-13 to 1983-03-07
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
comparable to guideline study with acceptable restrictions

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1983
Report date:
1983

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
GLP compliance:
yes
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
α,α,α-trifluoro-4-nitro-m-cresol
EC Number:
201-818-2
EC Name:
α,α,α-trifluoro-4-nitro-m-cresol
Cas Number:
88-30-2
Molecular formula:
C7H4F3NO3
IUPAC Name:
α,α,α-trifluoro-4-nitro-m-cresol
Test material form:
solid
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source of test material: Hoechst, Lamprecide FCL #1409, HRI No* 975297

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature, ambient conditions

Test animals

Species:
rat
Strain:
Crj: CD(SD)
Remarks:
COBS
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Kingston, New York, USA facility of Charles River Breeding Laboratories, Wilmington, Massachusetts, USA
- Age at study initiation: 7 - 9 weeks
- Housing: stainless steel wire mesh cages (67 in²)
- Diet: ad libitum, Purina Certified Rodent Chow (#5002)
- Water: ad libitum, automatic watering system
- Acclimation period: 2 weeks

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 50 ± 20
- Air changes (per hr): 10 - 15
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
corn oil
Details on exposure:
VEHICLE
- Amount of vehicle: 5 mL/kg bw
- Lot/batch no.: 101F-0141, Sigma Chemical Company, St. Louis, Missouri, USA
Details on mating procedure:
- Impregnation procedure: cohoused
- M/F ratio per cage: 1/1
- Proof of pregnancy: vaginal plug and sperm in vaginal smear referred to as day 0 of pregnancy.
Duration of treatment / exposure:
Day 6 to day 15 of gestation
Frequency of treatment:
daily
Duration of test:
20 days
Doses / concentrationsopen allclose all
Dose / conc.:
25 other: mg/5 mL/kg bw
Dose / conc.:
125 other: mg/5 mL/kg bw
Dose / conc.:
250 other: mg/5 mL/kg bw
No. of animals per sex per dose:
25 ♀/per dose
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: based on the results of a range finding study.

Examinations

Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
- Cage side observations were included.

BODY WEIGHT: Yes
- Time schedule for examinations: Day 0, 6, 9, 12, 15, 18, and 20

POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: ovaries, uterus
Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
Fetal examinations:
- External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
Statistics:
The litter or dam was considered the experimental unit for evaluation, although data on individual fetuses with abnormalities also were considered. Differences were considered significant at p < 0.05.
Dam body weight on Day 0 and the corrected and uncorrected change in weight between Days 0 and 20 were analyzed by analysis of variance, and, when significant, treatment means were compared with control means using Dunnett's multiple comparison test. Dam body weights on Days 6 and 20, gravid uterine weight, and corrected weight on Day 20 were analyzed by covariate analysis using Day 0 body weight as the covariate. Dunnett's test was performed on means adjusted for the covariate where covariate analyses indicated significant differences.
Number of corpora lutea; number of implants; implantation efficiency; number -and percent of live, resorbed, and dead fetuses; and sex ratio were analyzed using the Kruskal-Wallis test. Where significant differences were indicated, Dunn's test was performed. Mean fetus weight was analyzed by covariate analysis using the number of live fetuses as the covariate. Dunnett's test was performed on means adjusted for the covariate where covariate analysis indicated significant differences.
The number of litters with fetal gross, visceral, and skeletal abnormalities was analyzed by contingency table techniques (Chi²). Where overall significant treatment differences were indicated, treated groups were compared with the control group using the Chi² statistic for the appropriate 2x2 tables, correcting the significance levels for the number of comparisons being made.
The percent of litters with fetal gross, visceral, and skeletal abnormalities was analyzed using the Kruskal-Wallis test. Where significant differences were indicated, Dunn's test was performed.

Results and discussion

Results: maternal animals

General toxicity (maternal animals)

Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
Salivation following treatment (observed in all treatment groups). Reddish-brown vaginal discharge (associated with a placental sign) in one animal in the 25 mg/kg group. Flaccid body tone for one animal; pawing and rubbing of the cage bottom following treatment for one animal in the 125 mg/kg group. Yellow-stained muzzle and forepaws for two animals and pronation and lethargy following treatment for one animal in the 250 mg/kg group. In addition, one animal had a rough coat.
Mortality:
mortality observed, treatment-related
Description (incidence):
Two animals in the 250 mg/kg group died on Day 6 (the first day of treatment) and Day 12 of gestation, respectively.
Body weight and weight changes:
no effects observed
Description (incidence and severity):
There were no statistically significant differences in mean body weights and weight changes between Days 0 and 20 of gestation
Food consumption and compound intake (if feeding study):
not examined
Food efficiency:
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
no effects observed
Gross pathological findings:
effects observed, treatment-related
Description (incidence and severity):
Renal pelvic cavitation was noted in all groups, and indentations were observed in the cortex of the kidney for one animal each in the 25 mg/kg group and the 250 mg/kg group. In addition, one kidney in one animal was pitted, and a mottled kidney was reported for one animal in the 125 mg/kg group. Other necropsy observations included fused placentae for one animal and a darkened and slightly enlarged liver for one animal in the 125 mg/kg group.
Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
not examined
Histopathological findings: neoplastic:
not examined

Maternal developmental toxicity

Number of abortions:
no effects observed
Pre- and post-implantation loss:
no effects observed
Total litter losses by resorption:
no effects observed
Early or late resorptions:
no effects observed
Dead fetuses:
no effects observed
Changes in pregnancy duration:
no effects observed
Description (incidence and severity):
Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed
Changes in number of pregnant:
no effects observed

Effect levels (maternal animals)

open allclose all
Key result
Dose descriptor:
NOAEL
Effect level:
125 mg/kg bw/day
Based on:
test mat.
Basis for effect level:
mortality
Dose descriptor:
LOAEL
Effect level:
250 mg/kg bw/day
Based on:
test mat.
Basis for effect level:
mortality

Maternal abnormalities

Key result
Abnormalities:
no effects observed

Results (fetuses)

Fetal body weight changes:
no effects observed
Description (incidence and severity):
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): no effects observed
Reduction in number of live offspring:
no effects observed
Changes in sex ratio:
no effects observed
Changes in litter size and weights:
no effects observed
External malformations:
no effects observed
Skeletal malformations:
effects observed, non-treatment-related
Description (incidence and severity):
Unossified hyoids, unossified sternebrae, rudimentary ribs, and anomalies of the centra were found in control and treated groups in a nontreatmeht related pattern.
Visceral malformations:
effects observed, non-treatment-related
Description (incidence and severity):
Unilateral renal pelvic cavitation (anomaly) was found in control and treated groups with the following incidence: one fetus from one litter in the control group; two fetuses from two litters each in the 25 mg/kg group and 125 mg/kg group; and five fetuses from four litters in the 250 mg/kg group. In addition, one fetus from one animal in the 250 mg/kg group had bilateral renal pelvic cavitation. Although these data are not statistically significant, they may indicate a fetotoxic response or be an expression of delayed development due to compound-related fetal stress. Dilated ureters (anomaly), associated with the renal pelvic cavitation, were noted in one fetus in the control group and two fetuses in the 250 mg/kg group. A dilated ureter not associated with renal pelvic cavitation was noted in one fetus from one animal in the 125 mg/kg group. Observations for the high-dose group only included one case each of a small (anomaly) and an absent testis (malformation).

Effect levels (fetuses)

Key result
Dose descriptor:
NOAEL
Effect level:
250 mg/kg bw/day
Based on:
test mat.
Sex:
male/female
Basis for effect level:
visceral malformations

Fetal abnormalities

Key result
Abnormalities:
no effects observed

Overall developmental toxicity

Key result
Developmental effects observed:
no

Any other information on results incl. tables

Table 1: Maternal Toxicity

TMF mg/kg bw

 

0

25

125

250

Dams on study

25

25

25

25

Dams examined on Day 20

25

25

25

23

Dams with implantations

24

25

23

23

Percent with implantations

96

100

92

100

 

 

 

 

 

Corpora lutea, Mean

15

15

16

16

S.D.

1.7

1.7

2.3

1-8

 

 

 

 

 

Implantations, Mean

14

13

14

14

S.D.

3.1

4.1

3.3

4.1

 

 

 

 

 

Implantation efficiency, Mean

93.3

86.2

86.3

89.8

S.D.

18.21

25.54

19.69

23.54

 

 

 

 

 

Litters with live fetuses

24

25

23

23

Total live fetuses

332

317

297

299

Live fetuses,Mean

14

13

13

13

S.D.

3.1

3.9

3.4

4.7

 

 

 

 

 

Percent live fetuses, Mean

100.0

100.0

100.0

100.0

S.D.

0.00

0.00

0.00

0.00

 

 

 

 

 

Fetal weight (g), Mean

3.5

3.6

3.5

3.5

S.D.

0.18

0.29

0.26

0.22

 

 

 

 

 

Sex ratio [(M/M+F) X 100], Mean

51.9

54.7

48.7

46.7

S.D.

16.35

15.06

lb.86

18.88

 

 

 

 

 

Litters with resorbed fetuses

9

12

11

11

Total resorbed fetuses

14

17

16

26

 

 

 

 

 

Resorbed fetuses, Mean

1

1

1

1

S.D.

0.9

0.9

0.9

2.5

 

 

 

 

 

Percent resorbed fetuses, Mean

3.8

4.7

5.5

8.6

S.D.

5.80

5.93

7.09

16.73

 

Table 2: Fetal abnormalities

TMF mg/kg bw

 

0

25

125

250

Soft tissue:

 

 

 

 

Renal pelvic cavitation

1 (1)

2 (2)

2 (2)

6 (5)

Dilated ureters

1 (1)

1 (1)

0

2 (2)

Small testis

0

0

0

1 (1)

Absent testis

0

0

 

1 (1)

 

 

 

 

 

Skeletal

 

 

 

 

Malformed scapulae

1 (1)

0

0

0

Malformed/bent forelimbs

1 (1)

0

0

0

Bent ribs

1 (1)

0

0

0

Number in brackets represent the number of litters affected

Applicant's summary and conclusion

Conclusions:
In this developmental toxicity study similar to OECD guideline 414 (Hazleton Laboratories, 1983), the test substance showed no developmental toxicity.
Executive summary:

In a developmental toxicity study similar to OECD guideline 414 (Hazleton Laboratories, 1983), pregnant COBS® CD® (SD) Br rats (25/group) received the test substance by oral gavage at doses of 0 (corn oil vehicle), 25, 125, or 250 mg/kg bw/day on gestation days (GD) 6 - 15, inclusive. It was not specified whether doses were adjusted for percent active ingredient. On GD 20, all dams were sacrificed and all fetuses were examined for external malformations/variations. Approximately one-half of each litter was placed in Bouin’s fixative for subsequent visceral examination and the remainder stained for skeletal examination. All animals in the control, low-, and mid-dose groups survived until scheduled sacrifice. Two high-dose dams died during the treatment interval, one on GD 6 and the other on GD 12 and the study author stated that the deaths were treatment related. The only other clinical sign of toxicity was salivation which was observed in 0/25, 0/25, 2/25, and 22/25 (p < 0.01) animals in the 0, 25, 125, and 250 mg/kg bw/day groups, respectively. There were no significant differences in maternal body weights between the treated and control groups at any time during gestation. Food consumption was not measured. Therefore, the maternal toxicity LOAEL is 250 mg/kg bw/day based on mortality. The corresponding maternal toxicity NOAEL was 125 mg/kg bw/day. No treatment-related effects were observed for gravid uterine weights, number of fetuses/litter, pre- and postimplantation loss, numbers of corpora lutea/dam, number of implantations/dam, resorptions/dam, fetal body weights, or fetal sex ratios. No statistically significant differences in the incidence rates of any external, visceral, or skeletal malformations/variations were observed in the treated litters as compared to the controls.

Therefore, no treatment related teratogenic effects were abserved. The NOAEL for developmental toxicity is 250 mg/kg/day.